Yael L.

Yael L. Maxwell is Senior Medical Journalist for TCTMD and Section Editor of TCTMD’s Fellows Forum. She served as the inaugural media fellow for the Center for Health, Media & Policy at Hunter College from 2015 to 2016. Her 2022 news story about radiation exposure for structural imagers won the Occupational and Environmental Medicine Media Excellence Award from the American College of Occupational and Environmental Medicine and her 2021 feature story about expired cardiac devices won a Bronze Digital Health Award. Prior to working for CRF, Yael spent 2 years managing all research-related communications at the Lymphoma Research Foundation. She has also worked for the Editorial department of the PBS-affiliated science documentary series NOVA and the public affairs office of Brigham and Women’s Hospital in Boston, and she has contributed to Genewatch, the monthly publication of the Council for Responsible Genetics. Her work has been published in mental_floss, Refinery29, and ScienceNOW. Yael studied Environmental Science and Journalism at Boston University.

77%

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

85%

Examples:

  • The author does not disclose any potential conflicts of interest or sources of funding for the article.
  • The author is biased in favor of ticagrelor and against DAPT.

Conflicts of Interest

50%

Examples:

  • The author has contributed to Genewatch, the monthly publication of the Council for Responsible Genetics.
  • The author is a Senior Medical Journalist for TCTMD and Section Editor of TCTMD's Fellows Forum.

Contradictions

85%

Examples:

  • There are no other ARTICLES THEREFORE NO EXAMPLES
  • The study found that there was no significant difference in major adverse cardiovascular and cerebrovascular events between patients who continued DAPT for 12 months or those who discontinued aspirin and continued ticagrelor for one month.

Deceptions

90%

Examples:

  • The author claims that discontinuing aspirin and continuing ticagrelor as soon as one month after PCI for ACS patients is associated with less clinically-relevant and major bleeding than continuing DAPT over a longer period. However, this claim is not supported by the data presented in the article.
  • The author uses emotive language such as 'ultimate', 'another boost' and 'solo' to create a false impression of certainty and novelty.

Recent Articles

New Study Finds Aspirin Reduces Bleeding Complications After PCI for Heart Attack Patients

New Study Finds Aspirin Reduces Bleeding Complications After PCI for Heart Attack Patients

Broke On: Tuesday, 09 April 2024 A new study published in The Lancet found that stopping aspirin one month after percutaneous coronary intervention (PCI) for an acute coronary syndrome significantly reduces bleeding complications in heart attack patients. This is the first time a placebo-controlled trial has confirmed this finding, and it was presented at the American College of Cardiology 2024 Scientific Sessions on Sunday, April 7th.